Life Healthcare has agreed to sell its entire stake in Life Molecular Imaging (LMI) to Lantheus for $350 million upfront ($200 million after costs). The deal also includes potential earnout payments of up to $400 million based on LMI product milestones by 2034. Life Healthcare plans to return the net proceeds to shareholders within a year of the transaction's completion.